Clinical trials located in

Plérin

Plérin city is located in France. Currently, 6 clinical trials are being conducted in this city.

Plérin, located in Brittany, France, is a coastal city known for its picturesque landscapes and rich history. It boasts the Pointe du Roselier, offering stunning views of the English Channel. The city’s heritage is marked by the 16th-century Chapelle de la Madeleine, showcasing Brittany’s architectural elegance. Plérin is also renowned for its vibrant market, reflecting the local culture and gastronomy. The city’s commitment to preserving natural beauty is evident in its award-winning beaches and the Rosaires beach, a favorite among locals and visitors for its serene environment.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Sacituzumab trial for metastatic breast cancer patients

    This study is all about trying a medication named Sacituzumab Govitecan for individuals with a specific kind of breast cancer that has spread beyond the breast (metastatic) and is not affected by certain hormones or proteins. The goal is to see if this medicine can help people live longer by stopping the cancer from growing or spreading. This medicine will be compared with other usual treatments that your doctor may choose, such as paclitaxel or capecitabine. The study also aims to know the percentage of patients who see their cancer shrink as a result of the treatment. Furthermore, the study will also evaluate how the treatment impacts the overall well-being of the patients, through a series of questions related to physical, emotional, and social life.

    • Sacituzumab Govitecan-hziy
    • nab-Paclitaxel
    • Capecitabine
    • Paclitaxel
  • Testing a new trio of drugs for advanced and metastatic breast cancer

    This study, known as CAPItello-292, is testing a new combination of drugs to see if it can help treat advanced or spreading breast cancer. The drugs include one called capivasertib along with two others known as CDK4/6 inhibitors and another drug called fulvestrant. The study wants to see how well these work together and how safe they are. Firstly, they need to decide on the best dose of these drugs to use together. Then, the main part of the study will compare these drugs with the usual treatment – either of the CDK4/6 inhibitors with fulvestrant — to see which is better. Scientists will check the blood of the patients to see how much of the drugs are present. They also want to see how many people have side effects and how severe these are. Patients’ health will also be monitored, including heart tests, blood tests and checking vital signs. The ultimate goal is to see if this new treatment can slow down the growth of the cancer, or even shrink it. In simpler words, this is a study for people with a type of advanced breast cancer. It’s testing three drugs together — capivasertib, a CDK4/6 inhibitor, and fulvestrant. This study is made up of two parts. The first part is to decide on the right amount of these drugs to give at the same time. Then, they’ll test this against the usual treatment to see if it’s better. They’ll use blood tests to check how much of the drugs are in the body and will carefully watch for any side effects. They’ll also keep a close eye on people’s health overall. The main aim is to see if this new combination can stop the cancer from getting worse. The CAPItello-292 trial is aimed at patients with serious breast cancer that has started to spread. In this research, a new blend of three medicines, capivasertib, a CDK4/6 inhibitor, and fulvestrant, is being evaluated. First, researchers want to figure out the optimal dosing of these drugs when taken together. Then they’ll compare this combination to the standard treatment to see if it provides any additional benefits. They’ll take blood tests to track the amount of medication and continuously monitor for any potential side effects. The end goal is to see if this new drug mixture can slow or even decrease the growth of the cancer.

    • Capivasertib
    • Abemaciclib
    • Palbociclib
    • Ribociclib
    • Fulvestrant
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in France:

.